| KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors (NCT05906524) | Shanghai Kanda Biotechnology Co., Ltd. | 2024-04-15 |
| A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function (NCT06370819) | Novo Nordisk A/S | 2024-04-15 |
| Phase1, STP7 Cocaine Drug-Drug Interaction Study (NCT06273540) | Stalicla SA | 2024-04-15 |
| Phase 1 Study in Diabetes Mellitus(Fed) (NCT06551740) | Huons Co., Ltd. | 2024-04-15 |
| Sublingual Atropine Bioequivalence by Route of Administration (SABER) (NCT06366087) | Biomedical Advanced Research and Development Authority | 2024-04-15 |
| Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL (NCT06333509) | CARsgen Therapeutics Co., Ltd. | 2024-04-15 |
| A First-in-Human Safety Trial of MTX-463 (NCT06401213) | Mediar Therapeutics | 2024-04-15 |
| Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir (NCT06356194) | Atea Pharmaceuticals, Inc. | 2024-04-15 |
| Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC (NCT06356701) | The First Affiliated Hospital of Dalian Medical University | 2024-04-15 |
| CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers (NCT06358053) | Corregene Biotechnology Co., Ltd | 2024-04-15 |
| Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 (NCT06386653) | Tomsk National Research Medical Center of the Russian Academy of Sciences | 2024-04-14 |
| Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma (NCT06376721) | Beijing Tongren Hospital | 2024-04-14 |
| Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging (NCT05866679) | M.D. Anderson Cancer Center | 2024-04-12 |
| A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults (NCT06371534) | Qilu Pharmaceutical Co., Ltd. | 2024-04-12 |
| Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (NCT06233942) | BeOne Medicines | 2024-04-12 |
| A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers (NCT06348355) | AstraZeneca | 2024-04-12 |
| A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (NCT06341114) | Bio-Thera Solutions | 2024-04-12 |
| Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers (NCT06780124) | Eilean Therapeutics | 2024-04-12 |
| A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer (NCT06663839) | Light Chain Bioscience - Novimmune SA | 2024-04-12 |
| A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors (NCT06394622) | Fudan University | 2024-04-11 |
| The Effect of Repetitive Transcranial Magnetic Stimulation on Cognitive Improvement in Dementia With Lewy Bodies (NCT07122908) | Korea University Anam Hospital | 2024-04-11 |
| A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy (NCT06044025) | University of Arkansas | 2024-04-11 |
| MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma (NCT06042725) | Mayo Clinic | 2024-04-11 |
| 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery (NCT06048094) | Baptist Health South Florida | 2024-04-11 |
| PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (NCT06299410) | Intra-Cellular Therapies, Inc. | 2024-04-11 |
| Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NCT06295549) | The First Affiliated Hospital with Nanjing Medical University | 2024-04-11 |
| HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors (NCT06336707) | Hansoh BioMedical R&D Company | 2024-04-11 |
| Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke (NCT06344390) | The First Hospital of Hebei Medical University | 2024-04-10 |
| Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation (NCT06280768) | Beijing Suncadia Pharmaceuticals Co., Ltd | 2024-04-10 |
| Study of JMKX003142 Injection in Chinese Healthy Subjects (NCT06344533) | Jemincare | 2024-04-10 |
| A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (NCT06311578) | Johnson & Johnson Enterprise Innovation Inc. | 2024-04-10 |
| A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) (NCT06330064) | Daiichi Sankyo | 2024-04-10 |
| Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer (NCT06378047) | H. Lee Moffitt Cancer Center and Research Institute | 2024-04-10 |
| Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout (NCT06186219) | University of California, Los Angeles | 2024-04-10 |
| Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD) (NCT06150716) | Ionis Pharmaceuticals, Inc. | 2024-04-10 |
| Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (NCT05791409) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2024-04-10 |
| Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma (NCT06251180) | Guangzhou Lupeng Pharmaceutical Company LTD. | 2024-04-10 |
| A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants (NCT06348888) | Bayer | 2024-04-10 |
| A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men (NCT06337110) | H. Lundbeck A/S | 2024-04-10 |
| The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia. (NCT06674694) | Sichuan Kelun Pharmaceutical Co.,Ltd. | 2024-04-10 |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis (NCT06138132) | Stanford University | 2024-04-10 |
| Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure (NCT06348498) | Tasly Pharmaceutical Group Co., Ltd | 2024-04-09 |
| Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT) (NCT06795204) | Haisco-USA Pharmaceuticals, Inc. | 2024-04-09 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants (NCT06311760) | AstraZeneca | 2024-04-09 |
| A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (NCT06328673) | D2M Biotherapeutics Inc. | 2024-04-09 |
| Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression (NCT05565118) | Case Comprehensive Cancer Center | 2024-04-09 |
| Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma (NCT06048250) | City of Hope Medical Center | 2024-04-09 |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NCT06326411) | Nested Therapeutics, Inc | 2024-04-09 |
| A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam (NCT06327256) | Boehringer Ingelheim | 2024-04-09 |
| A Bioequivalence Study of Two Different PEG-rhGH Preparations. (NCT06331026) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-04-09 |
| Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir (NCT05589688) | University Hospital, Toulouse | 2024-04-09 |
| Safety Study of SLV213 for the Treatment of COVID-19. (NCT06146374) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-04-09 |
| A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (NCT06311786) | Biogen | 2024-04-08 |
| A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020) (NCT06273774) | Merck Sharp & Dohme LLC | 2024-04-08 |
| A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors (NCT06257680) | Aeonvital Biomedicine | 2024-04-08 |
| Evaluate the Distribution and Dynamic Behavior of TH-SC01 Cells in Vivo in Patients With Perianal Fistula (NCT06429241) | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 2024-04-08 |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) (NCT06462365) | Tr1X, Inc. | 2024-04-08 |
| T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor (NCT06484790) | Ting Deng | 2024-04-08 |
| Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants (NCT06346509) | Portal Therapeutics, Inc. | 2024-04-08 |
| A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers (NCT06304961) | AstraZeneca | 2024-04-08 |
| Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt) (NCT06318260) | Steen Hvitfeldt Poulsen | 2024-04-08 |
| Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects (NCT06379958) | Modern Biosciences Ltd | 2024-04-08 |
| Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions (NCT06588517) | Overseas Pharmaceuticals, Ltd. | 2024-04-08 |
| Safety and Feasibility of Intraoperative Visualization With Cytalux in Children (NCT06235125) | Ann & Robert H Lurie Children's Hospital of Chicago | 2024-04-08 |
| A Study of FB1003 in Healthy and Osteoarthritis Pain Subjects (NCT06343714) | 4B Technologies Limited | 2024-04-07 |
| Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RSS0343 Tablets in Healthy Subjects After Single and Multiple Oral Administration and the Effect of Food on the Pharmacokinetics of RSS0343 (NCT07101965) | Jiangsu HengRui Medicine Co., Ltd. | 2024-04-07 |
| Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease (NCT05898633) | University College, London | 2024-04-06 |
| Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial (NCT06812637) | Kafrelsheikh University | 2024-04-06 |
| Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne (NCT06316297) | Sanofi Pasteur, a Sanofi Company | 2024-04-05 |
| Β-Thalassemia Treatment with KL003 Cell Injection (NCT06280378) | Kanglin Biotechnology (Hangzhou) Co., Ltd. | 2024-04-05 |
| A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age (NCT06354257) | GlaxoSmithKline | 2024-04-05 |
| Study of ARO-CFB in Adult Healthy Volunteers (NCT06209177) | Arrowhead Pharmaceuticals | 2024-04-05 |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition (NCT06218628) | Fox Chase Cancer Center | 2024-04-05 |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC (NCT06096038) | UNC Lineberger Comprehensive Cancer Center | 2024-04-05 |
| Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT06377683) | The First Affiliated Hospital of Xiamen University | 2024-04-05 |
| Ultrasonic Neuromodulation for Treatment of PTSD (NCT06135064) | University of Utah | 2024-04-05 |
| "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (NCT06067061) | Institut Curie | 2024-04-05 |
| Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah (NCT06003179) | University Health Network, Toronto | 2024-04-05 |
| Tumor Treating Fields for Locally Advanced NSCLC (NCT06124118) | University of Utah | 2024-04-04 |
| Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State. (NCT06483243) | Chong Kun Dang Pharmaceutical | 2024-04-04 |
| A Study of Sovilnesib in Subjects With Ovarian Cancer (NCT06084416) | Volastra Therapeutics, Inc. | 2024-04-04 |
| Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors (NCT06276491) | Xencor, Inc. | 2024-04-04 |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors (NCT05932862) | Exelixis | 2024-04-03 |
| A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study (NCT06271252) | OriCell Therapeutics Co., Ltd. | 2024-04-03 |
| A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours (NCT06305247) | Ipsen | 2024-04-03 |
| Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension (NCT04500574) | Massachusetts Eye and Ear Infirmary | 2024-04-03 |
| AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus (NCT06265220) | Artiva Biotherapeutics, Inc. | 2024-04-03 |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (NCT06051695) | A2 Biotherapeutics Inc. | 2024-04-03 |
| A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants (NCT06345794) | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 2024-04-03 |
| [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (NCT06229366) | Eli Lilly and Company | 2024-04-03 |
| A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy (NCT06351904) | Ractigen Therapeutics. | 2024-04-03 |
| A Study of LY3841136 in Overweight and Obese Participants (NCT06345066) | Eli Lilly and Company | 2024-04-03 |
| Effectivity of Allogenic Umbilical Cord Mesenchymal Stem Cells Conditioned Media for Osteoarthritis of the Knee Joint (NCT06688318) | Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia | 2024-04-03 |
| Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma (NCT06327477) | Northwestern University | 2024-04-02 |
| Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer (NCT06026657) | Margaret Gatti-Mays | 2024-04-02 |
| Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants (NCT06397508) | Agomab Spain S.L. | 2024-04-02 |
| A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer (NCT06283303) | China Medical University, China | 2024-04-02 |
| First In Human Study of CX-2051 in Advanced Solid Tumors (NCT06265688) | CytomX Therapeutics | 2024-04-02 |
| The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) (NCT06291415) | Hutchmed | 2024-04-02 |
| A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation (NCT06312787) | Vertex Pharmaceuticals Incorporated | 2024-04-02 |